MERCK & CO INC

We couldn’t find any news about Merck & Co. Inc., so a related article can’t be created without additional information.

Merck’s stock gains optimism amid mixed analyst ratings, a breakthrough mRNA cancer vaccine partnership, and rising option activity—what this means for investors.

Merck’s record‑high stock, driven by analyst upgrades, strong immuno‑oncology pipeline and potential Gilead tie‑up, signals continued growth for pharma investors.

Merck’s Q2 2026 earnings show a $1.3 B GAAP loss amid a $5.7 B acquisition charge, yet revenue tops expectations, raising questions on future cash flow and valuation pressure.

Merck’s new royalty‑free licensing deals enable a monthly oral HIV prevention pill in 129 countries, boosting affordable access and global health impact.

Merck’s FDA approval of KEYTRUDA + Padcev combo offers new hope for muscle‑invasive bladder cancer patients, boosting treatment options and investor outlook.

Merck stock dips after six‑day rally, spurred by the Alzheimer’s drug pullback and cautious market mood—find out what’s driving the pullback and the future outlook.

Merck & Co. partners with EXEL to launch a late‑stage colorectal cancer study, aiming to accelerate innovative treatments and expand its oncology portfolio.

Merck’s strategic focus on nanomedicine and hematologic oncology positions it to capture projected $550 bn and $128 bn markets, backed by strong finance and partnership power.

Merck’s rise to Bank of America’s “US 1” list, active institutional buys, and top‑executive share purchases highlight why investors see it as a solid, liquid long‑term pharma core.